Horino N
Cancer. 1982 Aug 15;50(4):659-67. doi: 10.1002/1097-0142(19820815)50:4<659::aid-cncr2820500407>3.0.co;2-l.
The effect of various intermittent combination chemotherapies on the immune status of 30 patients with malignancies was examined 1-3 weeks after they received their last injection. PWM-induced polyclonal B-cell activation of lymphocytes from patients treated with combination chemotherapies that included doxorubicin was impaired despite a normal 3H-thymidine uptake by lymphocytes stimulated with PHA, PWM, and insoluble SPA. This suppressive effect was always found in patients with ALL. However, in patients with solid tumors, PWM-induced immunoglobulin production returned to normal 7-8 weeks after the last doxorubicin injection. Serum immunoglobulin levels in patients treated with doxorubicin were slightly lower than in those treated without doxorubicin. It is hypothesized that doxorubicin may change the lymphocyte surface membrane and interrupt the T- and B-cell interaction that is needed for immunoglobulin production.
在30例恶性肿瘤患者接受最后一次注射后1 - 3周，研究了各种间歇联合化疗对其免疫状态的影响。尽管用PHA、PWM和不溶性SPA刺激的淋巴细胞对³H - 胸腺嘧啶的摄取正常，但接受包含阿霉素的联合化疗的患者，其淋巴细胞的PWM诱导的多克隆B细胞活化受损。这种抑制作用在所有白血病患者中均有发现。然而，在实体瘤患者中，最后一次阿霉素注射后7 - 8周，PWM诱导的免疫球蛋白产生恢复正常。接受阿霉素治疗的患者血清免疫球蛋白水平略低于未接受阿霉素治疗的患者。据推测，阿霉素可能会改变淋巴细胞表面膜，并中断免疫球蛋白产生所需的T细胞和B细胞相互作用。
